Who filed the Form 25 related to CRNX?

The Form 25 is filed by Nasdaq Stock Market LLC, which certifies it has reasonable grounds to believe it meets all requirements for filing and has caused the notification to be signed by an authorized person.

Nasdaq moves to delist Crinetics Pharmaceuticals

Q: What does the Form 25 filed for CRNX common stock mean?

The Form 25 indicates that Crinetics Pharmaceuticals, Inc. common stock is being removed from listing and/or registration under Section 12(b) of the Exchange Act. Nasdaq Stock Market LLC certifies it has followed its rules and applicable 17 CFR 240.12d2-2 procedures.

Q: Which securities of CRNX are covered by this Form 25?

The filing covers Common Stock of Crinetics Pharmaceuticals, Inc. listed on Nasdaq Stock Market LLC, and serves as notification of its removal from listing and/or registration under Section 12(b).

Q: What regulations are cited in the CRNX Form 25 notice?

The notice references 17 CFR 240.12d2-2(a)(1)-(4), and states compliance with 17 CFR 240.12d2-2(b) by the exchange and 17 CFR 240.12d2-2(c) by the issuer for withdrawal of the class from listing and registration.

Q: What is the issuer information for CRNX in the Form 25?

The issuer is Crinetics Pharmaceuticals, Inc., with principal executive offices at 10222 Barnes Canyon Road, Bldg. #2, San Diego, California 92121, and telephone number 858-703-6540, as stated in the notice.

Crinetics Pharmaceuticals, Inc. (CRNX) has had its common stock the subject of a Form 25 filing by Nasdaq Stock Market LLC to remove the class of securities from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

25-NSE

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. (CRNX) has had its common stock the subject of a Form 25 filing by Nasdaq Stock Market LLC to remove the class of securities from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The notification states that the exchange has complied with its rules and with 17 CFR 240.12d2-2(b), and that the issuer has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing withdrawal of the class from listing and registration. The filing is signed on behalf of Nasdaq by an authorized officer.

Key Figures

Issuer telephone number: 858-703-6540 Zip code of principal executive offices: 92121 Commission File Number: 001-38583

3 metrics

Issuer telephone number 858-703-6540 Telephone number for Crinetics Pharmaceuticals, Inc. principal executive offices

Zip code of principal executive offices 92121 ZIP code for Crinetics Pharmaceuticals, Inc. address in San Diego, California

Commission File Number 001-38583 Exchange Act registration file number for Crinetics Pharmaceuticals, Inc.

Key Terms

Form 25, Section 12(b) of the Securities Exchange Act of 1934, 17 CFR 240.12d2-2, withdrawal of the class of securities from listing and registration

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) of the Securities Exchange Act of 1934 regulatory

"under SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

withdrawal of the class of securities from listing and registration regulatory

"governing the voluntary withdrawal of the class of securities from listing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 25 filed for CRNX common stock mean?

The Form 25 indicates that Crinetics Pharmaceuticals, Inc. common stock is being removed from listing and/or registration under Section 12(b) of the Exchange Act. Nasdaq Stock Market LLC certifies it has followed its rules and applicable 17 CFR 240.12d2-2 procedures.

Which securities of CRNX are covered by this Form 25?

The filing covers Common Stock of Crinetics Pharmaceuticals, Inc. listed on Nasdaq Stock Market LLC, and serves as notification of its removal from listing and/or registration under Section 12(b).

What regulations are cited in the CRNX Form 25 notice?

The notice references 17 CFR 240.12d2-2(a)(1)-(4), and states compliance with 17 CFR 240.12d2-2(b) by the exchange and 17 CFR 240.12d2-2(c) by the issuer for withdrawal of the class from listing and registration.

What is the issuer information for CRNX in the Form 25?

The issuer is Crinetics Pharmaceuticals, Inc., with principal executive offices at 10222 Barnes Canyon Road, Bldg. #2, San Diego, California 92121, and telephone number 858-703-6540, as stated in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/01/2026 - 09:51 AM EDT Accepted by SEC EDGAR 09/01/2026 - 09:50 AM EDT

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38583

Issuer:	Crinetics Pharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	10222 Barnes Canyon Road
	Bldg. #2
	San Diego	CALIFORNIA	92121
Telephone number:				858-703-6540

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-09-01	By	Katelin Rowe		CDO Analyst
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR